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Abstract
ThePI3K/Aktpathwayregulatesvariousstress-relatedcellularresponsessuch ascellsurvival,cell proliferation,metabolismand
protein synthesis. Many cancer cell types display the activation of this pathway, and compounds inhibiting this cell survival
pathway have been extensively evaluated as anti-cancer agents. In addition to cancers, several human viruses, such as HTLV,
HPV, HCV and HIV-1, also modulate this pathway, presumably in order to extend the life span of the infected target cells for
productive viral replication. The expression of HIV-1 Tat protein exhibited the cytoprotective effect in macrophages and a
human microglial cell line by inhibiting the negative regulator of this pathway, PTEN. This cytoprotective effect of HIV-1
appears to contributeto the long-term survival andpersistent HIV-1productioninhuman macrophagereservoirs. In this study
we exploited the PI3K/Akt dependent cytoprotective effect of Tat-expressing CHME5 cells. We screened a collection of
compounds known to modulate inflammation, and identified three novel compounds: Lancemaside A, Compound K and
Arctigenin that abolished the cytoprotective phenotype of Tat-expressing CHME5 cells. All three compounds antagonized the
kinase activity of Akt. Further detailed signaling studies revealed that each of these three compounds targeted different steps
of the PI3K/Akt pathway. Arctigenin regulates the upstream PI3K enzyme from converting PIP2 to PIP3. Lancemaside A1
inhibited the movement of Akt to the plasma membrane, a critical step for Akt activation. Compound K inhibited Akt
phosphorylation. This study supports that Tat-expressing CHME5 cells are an effective model system for screening novel PI3K/
Akt inhibitors.
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Introduction
Viral infections alter numerous cellular signaling pathways.
Among these pathways, the PI3K/Akt cell survival pathway is
activated by several key human pathogenic viruses such as human
papillomavirus (HPV; [1]), hepatitis virus C (HCV; [2]), human T
cell leukemia virus (HTLV; [3]) and human immunodeficiency
virus Type 1 (HIV-1; [4,5,6,7,8]). This virus-induced activation of
PI3K/Akt pathway involves specific viral proteins such as E6/E7
of HPV, NS5A of HCV, Tax of HTLV and Tat of HIV-1
[1,3,4,9]. Interestingly, in contrast to other viral proteins that
activate the PI3K/Akt pathway, the expression of Tat appears to
inactivate Phosphatase and tensin homolog (PTEN), the negative
regulator of PI3K/Akt pathway [8,10]. The genetic inactivation of
PTEN is also closely tied to the development of human cancers
[11,12]. Cell transformation is the consequence of direct PI3K/
Akt activation by onco-viruses (i.e. HPV, HCV and HTLV)
[1,3,9]; and indeed, the PI3K/Akt pathway is highly activated in
many cancer cell types [13]. Many pharmacological PI3K/Akt
inhibitors have been extensively evaluated as potential anti-cancer
agents, which can abolish the capability of cancer cells to extend
their life span against anti-cancer pressures such as cellular
immune response and inflammation. Structure-based drug design
against various cellular kinases involved in the PI3K/Akt pathway
has been extensively used to search for anti-PI3K/Akt agents [14].
Recently, a non-human cell line that overexpressed human Akt
kinase was also used for screening of Akt inhibitors [15]. Even with
these broad efforts, PI3K/Akt inhibitors that are safe and effective
for clinical use remain limited.
The expression of HIV-1 Tat protein in the human microglial
CHME5 cell line, as well as human primary macrophages,
activates the PI3K/Akt pathway upon exposure to cellular stresses
by reducing the level of PTEN, rendering a strong resistance to
extracellular stresses such as LPS or nitric oxide [7,8,16]. We
believe that this enhanced cell survival phenotype of Tat-
expressing human microglia and macrophages plays an important
role for the establishment of long-lived HIV-1 reservoirs in the
CNS [17,18,19,20], which in turn induces neuronal death and
HIV-1 associated neurodegenerative diseases [21,22].
In this report, we employed the Tat-induced cytoprotective
phenotype of CHME5 cells for screening of anti-PI3K/Akt agents
from a collection of chemical compounds known to modulate
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21781cellular inflammation, which is one of the key cellular stresses
associated with viral infection and pathogenesis. We identified
three compounds: Lancemaside A1 (LA), Compound K (CK) and
Arctigenin (AR) that effectively abolished the Tat-induced
cytoprotective phenotype of Tat-expressing CHME5 cells. Impor-
tantly, these three compounds negatively modulated three
different steps of the PI3K/Akt cell survival network, PI3K, Akt
activation and Akt kinase activity.
Materials and Methods
Reagents, cell lines and virus
The previously established CHME5 cell lines were used for this
study [7]. In short, CHME5 cells were transfected with pcDNA3.1
hygromycin (control) or pcDNA-Tat101 (tat). Human lung fibro-
blasts (HLF; purchased from ATCC) were also used for this study,
and the cells were maintained in 10% FBS in DMEM media.
Adenoviruses: Ad-eGFP and Ad-Akt-PH-eGFP were previously
established [7]. Antibodies used in these studies were purchased
from Cell Signaling.
Chemicals
Lipopolysaccharide (LPS; E. coli serotype O26:B6), cyclohexi-
mide (CHX), puerarin, apigenin, aucubin, quercetin and kaem-
pherol, isophytolased were purchased from Sigma (St. Louis, MO,
USA). Silybinin and silymarin were prepared according to
previously reported methods [23]. Naringenin, nobiletin, tanger-
etin poncirin and naringin were isolated from the immaturus
fructus of Citrus unshiu and Poncirus trifoliate according to previously
reported methods [24]. Ginsenoside Rb1 and ginsenoside Rg3
were isolated from the rhizome of Panax ginseng Meyer according to
the previously reported method [25]. Kalopanaxsaponin B was
isolated from the stem bark of Kalopanax pictus according to the
previously reported method [26]. Lancemasides were isolated
from the rhizome of Codonopsis lanceolata according to the
previously reported method [27]. Soyasaponin B was isolated
from soybean according to the previously reported method [28].
Glycitein and tectoridin were isolated from the flos of Pueraria
thunbergiana as previously described [29]. Compound K and
Lancemaside A1 purifies were greater than 95%. Arctigenin
purity was greater than 93%. The three lead compound chemicals
were dissolved in DMSO.
Screening protocol using the Tat-expressing CHME5 cell
line
CHME5 subline cells expressing Tat protein were treated with
50 mg/ml LPS and 10 mg/ml CHX stress in the presence or
absence of 10 mM drugs, and the live/dead assay (Invitrogen) was
performed on CHME5 cells as per the manufacturer’s protocol.
Cell images were captured with a fluorescence microscope and
then dead cells (red) and live cells (green) were counted manually.
A representative data set is shown in Data S1. Data S2 shows the
cell death for CHME5 control cells treated under different drug
conditions.
Western blot analysis
For monitoring the changes in Akt, pAkt, GSK3b and pGSK3b
levels, Tat-expressing CHME5 cell subline was exposed to LPS/
CHX in the presence or absence of three compounds for
90 minutes. The levels of total Akt and pAkt proteins were
determined and used as a ratio to normalize the data. Complete
data set for mean and standard deviations for the western blots is
shown in Supplementary Table S1. For PDK1, cells were treated
with the three compounds (20 mM) with and without LPS/CHX
stress for 20 minutes. The level of pPDK1 was normalized to b-
actin and labeled below the bands. The cell culture conditions for
each western analysis are described in the figure legends.
Akt membrane migration
One million Tat-expressing CHME5 cells were pre-treated with
the three compounds (20 mM) for 20 minutes. Then cells were
treated with and without LPS/CHX stress for 60 minutes. Lysates
were prepared from an equal number of the treated cells using a
compartmental protein extraction kit (Millipore). The membrane
extract lysates were analyzed by western dot blot (Echelon) and
visualized with anti-PIP3 antibody. A standard curved using
known amounts of PIP3 was generated (Data S3) and then used to
determine the quantity of PIP3 in the treated cell lysates. The
band densities were calculated and normalized by PTEN protein,
used as an internal loading control. For Adenovirus studies, HLF
cells were pre-treated with the three compounds (20 mM) for
20 minutes before incubation with 100 nM EGF for 40 minutes.
Akt plasma membrane localization was visualized by the
movement of Akt-PH-eGFP using a fluorescence microscope
(Zeiss).
Results
Tat-induced cytoprotective phenotype as a screening
tool for anti-PI3K/Akt agents
We previously reported that the expression of HIV-1 Tat
protein elevates the cytoprotective phenotype of human primary
macrophages and a human microglial cell line, CHME5 [7,8].
To monitor the cytoprotective phenotype of the Tat-expressing
CHME5 cells, we determined cell death by imaging cells for
fluorescence using ethidium homodimer for dead cells (red) and
calcein for live cells (green) (Data S1). Data from three experiments
were compiled and are shown in Figure 1A. CHME5 control cells
(control) stably transfected with pcDNA3.1-hygromycin exhibit
,16% cell death upon the co-treatment with lipopolysaccharide
(LPS, 50 mg/ml) and cycloheximide (CHX, 10 mg/ml), while the
Tat-expressing CHME5 cells (tat) show a low baseline cell death
(,3%) even in the presence of the LPS/CHX treatment. Both
control and Tat-expressing CHME5 cell lines displayed 4% or less
death when cultured without LPS/CHX.
Identifying compounds that show anti-cytoprotective
effects in Tat expressing CHME5 cells
Twenty-five compounds were previously isolated from parental
chemical libraries and selected for their ability to modulate
inflammatory stress responses. We investigated if these compounds
were able to inhibit the cytoprotective phenotype in Tat-expressing
CHME5 cells. As shown in Figure 1B (see ‘‘*’’), among the 25
compounds tested at 10 mM, three compounds: Lancemaside A1
(LA), Arctigenin (AR) and Compound K (CK) induced cell death
upon exposure to LPS/CHX. Importantly, cells treated with
Lancemaside A1 and Compound K had similar cell death as
compared to control (empty vector) CHME5 cell line in the absence
of the LPS/CHX stress (Figure 1A) at the tested concentrations,
whereas cells treated with Arctigenin alone showed roughly 6% cell
death. These data led us to select the top three compounds that
abolish the Tat-induced cytoprotective phenotype of CHME5 cells
presumably by antagonizing PI3K/Akt pathway, which is the
mechanism that elevates the survival capability of the Tat-
expressing CHME5 [7,16]. Next, dose concentration curves (5,
10, 15 and 20 mM) for the three drugs were determined. As shown
in Figure 2, with an increase in drug concentration, a higher
percentage of CHME5 cell death was detected in the LPS/CHX
A Novel Screening System for PI3K/Akt Inhibitors
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cell death (,5%), indicating the absence of the cytotoxicity of these
three compounds at the tested concentrations.
Determining the effects of the screened compounds on
Akt activation and kinase activity
Next, we tested if Lancemaside A1, Arctigenin and Compound
K can modulate the activation of Akt kinase, because Akt is a key
molecule for PI3K/Akt survival pathway. Western blot analysis
was used to monitor the phosphorylation of Akt kinase at three
different drug concentrations (5, 10, 20 mM, Figure 3). Tat-
expressing CHME5 cells were treated in the presence or absence
of these compounds and LPS/CHX stress for 90 minutes. Lysates
were than prepared and analyzed by western blot analysis to
examine the levels of total Akt, phospho-specific Akt (pAKT,
S473) and b-actin, used as a loading control.
As shown in Figure 3, the Tat-expressing CHME5 cells exhibited
low levels of Akt phosphorylation (pAkt) without any stress (control
lanes), whereas cells treated with LPS/CHX stress significantly
induced the phosphorylation of Akt, which explains the strong
survival phenotype. However, Tat-expressing CHME5 cells treated
with the three different compounds have decreased levels of pAkt in
a dose dependent manner (Figure 3). The relative density of each
pAkt band was normalized with the total Akt level for each
condition and then the fold changes in pAkt levels as compared to
the LPS/CHX treatment groups were calculated. The averages of
two experiments are shown below the western blot for each of the
three compounds (Figure 3). All three compounds, particularly
Lancemaside A1, effectively blocked the LPS/CHX stress induced
pAkt in the Tat-expressing CHME5 cells, which explains the
compound-induced loss of cell survival phonotype upon LPS/CHX
treatment (Figure 2). Next, we monitored by western blot analysis
the phosphorylated form of GSK3b (pGSK3b), total GSK3b,a n d
b-actin. GSK3b is a substrate of Akt kinase and is inactivated upon
phosphorylation. Similarly, the fold change of the normalized
pGSK3b level upon the LPS/CHX treatment was used to compare
Figure 1. Compounds screened for inhibiting cytoprotective effect. (A) CHME5 control cells and Tat-expressing CHME5 cells were treated
with (open bars) and without (closed bars) 50 mg/ml LPS and 10 mg/ml cycloheximide (LPS/CHX) to show the baseline level of death due to external
stress (,3%). Induction of cell death by LPS/CHX stress is denoted by ‘‘#’’ for the CHME5 control cells. (B) The Tat-expressing CHME5 cells were
treated with 25 different drugs (10 mM) in the presence or absence of LPS/CHX for 24 hours. Cell death was determined using the Live/Dead assay
(Invitrogen). Arctigenin, Compound K and Lancemaside A1 were the most potent compounds that prevented the cytoprotective effect of Tat during
LPS/CHX stress and are marked with asterisks (*). Data are plotted mean and SEM for 2–3 independent experiments for each drug.
doi:10.1371/journal.pone.0021781.g001
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phosphorylation. As shown in Figure 3, the levels of pGSK3b were
decreased correspondingly with increasing concentrations of the
three compounds. Collectively these data support that the cell death
phenotype (Figure 1), which was first used to screen these
compounds, is Akt dependent and that the three compounds are
involved in reducing the pAkt level in the cell.
Evaluating the effects of the screened compounds on
PI3K activity and PTEN
While Lancemaside A1, Arctigenin and Compound K reduced
Akt kinase activity and phosphorylation, it is possible that these
three compounds might target different upstream regulation steps
of the PI3K/Akt pathway. First, we investigated the effects of the
screened compounds on PI3K activity by determining the level of
PIP3 at the plasma membrane. This was done by employing a
western dot blot-based assay and quantitating PIP3 level using a
standard curve (Data S3). As shown in Figure 4A, the LPS/CHX
treatment alone increased the level of PIP3, which is the key initial
signature of PI3K pathway activation. Interestingly, Arctigenin
reduced the level of PIP3 in the Tat-expressing CHME5 cells
treated with the LPS/CHX stress, while neither Lancemaside A1
nor Compound K affected the levels of PIP3. Wortmannin is a
well-known PI3K inhibitor and was used as a control to inhibit
PIP3 induction in the presence of LPS/CHX (Figure 4A). These
data suggest that unlike Lancemaside A1 and Compound K,
Arctigenin likely targets the upstream PIP3 effector of the PI3K/
Akt pathway.
Next, we examined if the screened compounds independently
regulate the PTEN level within cells. PTEN serves as the key
negative regulator of the PI3K/Akt pathway by converting PIP3 to
PIP2.ArctigeninmaybeincreasingthePTENlevel,which results in
thereductionofthe PIP3levelobservedinFigure4A.Therefore,we
tested if the screened compounds affect the expression level of
PTEN in the Tat expressing CHME5 cells upon exposure to LPS/
CHX stress. As shown in Figure 4B, none of the three screened
compounds altered PTEN protein levels at the tested drug con-
centrations. Thus we conclude from these data that the PI3K/Akt
pathway inhibition by the three compounds is PTEN independent.
Importantly, since we did not observe an increase in PTEN levels
during Arctigenin treatment, the reduction of PIP3 level by this
compound is likely due to the direct inhibition of PI3K activity.
Determining the effects of the screened compounds on
PDK1
PDK1 is a direct downstream kinase of PI3K and activates the
membrane bound Akt protein. First, we performed a time course
to shown that LPS/CHX treatment of Tat-expressing CHME5
cells led to an increase in phospho-PDK1 (pPDK1) level. We
found that the maximum pPDK-1 was obtained within 10 minutes
of LPS/CHX treatment and was maintained for more than
60 minutes (Figure 5A). Next, we examined the effect of these
three compounds on pPDK1 levels, which were evaluated
20 minutes after treatment. As shown in Figure 5B, neither
Lancemaside A1 nor Compound K influenced the levels of
pPDK1 induced by LPS/CHX treatment, while only Arctigenin
reduced the levels of pPDK1 in a concentration dependent
manner, reaching untreated control levels with 20 mM Arctigenin.
These data suggest that both Lancemaside A1 and Compound K
likely target effectors downstream of PDK1. The inhibition of the
PDK1 phosphorylation by Arctigenin was expected because it
targets PI3K (Figure 4A), which phosphorylates PDK1.
Examining the effects of the screened compounds on the
Akt membrane migration
Akt is phosphorylated by PDK1 at the plasma membrane [30].
We have established that Arctigenin inhibits PI3K, thus blocking
PDK1 phosphorylation of Akt. However, both Compound K and
Lancemaside A1 may use different mechanism(s) to inhibit pAkt
levels in the cell. We postulated that inhibiting the movement of
Akt to the plasma membrane might be one potential mechanism
to explain pAkt inhibition by these two drugs. We used two
independent methods to address this. First, we extracted the
membrane fraction using the compartmental protein extraction
protocol on treated cells to determine the total amount of Akt by
Figure 2. Dose dependent cell death curves of Tat-expressing
CHME5 cells. The Tat-expressing CHME5 cell subline was incubated
with four concentrations (5, 10, 15 and 20 mM) of Arctigenin,
Compound K and Lancemaside A1 in the presence (black square) and
absence (open square) of LPS/CHX stress. Cell death was determined
using the Live/Dead assay and plotted as mean with SEM. See Data S1
for the live and dead cell staining of the Tat-expressing CHME5 cells
with the three compounds at 10 mM.
doi:10.1371/journal.pone.0021781.g002
A Novel Screening System for PI3K/Akt Inhibitors
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e21781immunoblotting. As shown in Figure 6A, Lancemaside A1
reduced the level of Akt at the membrane, whereas Arctigenin
and Compound K had less inhibition on Akt trafficking to the
plasmid membrane. PTEN was used as a loading control, since it
is located at the plasma membrane and none of the drugs influence
PTEN protein levels in the cell (Figure 4B). To further examine
Akt membrane localization, we transduced human lung fibroblast
cells with Adenovirus expressing Akt-PH-eGFP fusion protein or
eGFP protein only. As shown in Figure 6B, 24 h after transduction
cells were treated with epithelial growth factor (EGF). Control cells
(control picture), transduced with eGFP and treated with EGF,
had only cellular localization of eGFP. Positive control cells (EGF
picture) had punctate Akt-PH-eGFP at the plasma membrane,
whereas cells treated with EGF and Lancemaside A1 (EGF + LA
picture) showed only cellular distribution of Akt-PH-eGFP, similar
to control cells. Since it is assumed that Lancemaside A1 does not
affect the activity of PI3K, it appears to inhibit Akt movement to
the plasma membrane through inhibition of the PH domain. We
Figure 3. Examining the effects of the screened compounds on phosphorylation of Akt and GSK3b. Western blot analysis was performed
on Tat-expressing CHME5 cell lysates treated with and without LPS/CHX in the presence of the three different drug compounds at 5, 10, and 20 mM
concentrations for 90 minutes. Blots were probed for antibodies against phospho-Akt (pAkt), total Akt (Akt), phospho-GSK3b (pGSK3b), total GSK3b
(GSK3b) and b-actin. The changes in amount of pAkt and pGSK3b levels were determined, and the mean values of the duplicates were indicated
below each blot. The control lane, no LPS/CHX and drug, were set to 1. Data are representative of two independent experiments.
doi:10.1371/journal.pone.0021781.g003
Figure 4. Determining the effects of three screened compounds on membrane PIP3 and PTEN levels. (A) Tat-expressing CHME5 cells
were treated with and without LPS/CHX in the presence of the three different drug compounds at 20 mM for 20 minutes. Cell lysates were prepared
for determining the membrane PIP3 level. Data were calculated by generating a standard curve of known concentrations for PIP3 provided from the
manufacturer (Data S2). Control (Con), no treatment; LPS, 50 mg/ml LPS and 10 mg/ml cycloheximide; Lancemaside A1 (LA), Arctigenin (AR),
Compound K (CK) and Wortmannin (WM). (B) Tat-expressing CHME5 cells were treated in the presence or absence of LPS/CHX and 5, 10, and 20 mM
of each drug for 20 minutes. Cellular membrane fractions were processed and examined by western blot analysis for PTEN. b-actin was used as a
loading control. The fold changes in the PTEN level were determined as described in methods.
doi:10.1371/journal.pone.0021781.g004
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inhibits the localization of Akt to the plasma membrane, whereas
Arctigenin and Compound K have little to no effect on Akt
movement to the plasma membrane.
Evaluating the effects of the screened compounds on
two Akt down stream signals: mTOR and Bad
Next, we tested the influence of the screened compounds on two
additional Akt downstream effectors, mammalian target of
rapamycin (mTOR) and Bad. mTor has many cellular roles
including regulation of cell growth, proliferation, survival, protein
synthesis and metabolic homeostasis [31]. Bad appears to be
involved in regulating metabolism and apoptosis [32]. As shown in
Figure 7A and 7C, the LPS/CHX stress induced the phosphor-
ylation of both mTOR (p-mTor) and Bad (pBad) in a time
dependent manner, reaching maximum levels of phosphorylation
at 105 minutes for both proteins. Cells treated with Lancemaside
A1 and Arctigenin showed reduced levels of p-mTOR (Figure 7B)
and pBAD (Figure 7D). Interestingly, Compound K treatment
inhibited the level of pBad, but not p-mTOR. Possibly, the Akt
inhibition mechanism of Compound K, which showed a relatively
mild inhibitory effect on the upstream effectors of the PI3k/Akt
pathway, appears to display differential downstream effects
compared to the other two compounds.
Discussion
Inhibition of the PI3K/Akt cell survival pathway is a highly
attractive target for anti-cancer therapy. Many human cancer
types display the activation of this pathway, enabling the cancer
cells to survive and escape from anti-cancer responses. Impor-
tantly, several human onco-viruses, such as HPV, HTLV and
HCV, also activate the PI3K/Akt pathway [1,3,4,9]. The
activation of the PI3K/Akt pathway has been considered as an
important cellular event that viruses employ to ensure long-term
and productive viral replication by extending the life span of the
infected cells, and consequently leading to cell transformation. In
addition, HIV-1 indirectly hijacks this pathway in macrophages by
inhibiting the negative regulator of the pathway, PTEN, which
extends the life span of the infected macrophages exposed to
various virus-induced toxic stresses and contributes to the
establishment of long-lived viral reservoirs [7,8]. Thus, anti-
PI3K/Akt agents could serve not only as effective anti-cancer
drugs but also as anti-viral agents.
In this report, we employed the HIV-1 Tat-expressing CHME5
cell line, which exhibits an enhanced cell survival phenotype
against LPS/CHX stress by a PI3K/Akt dependent manner, to
Figure 5. Examining the effects of the screened compounds on PDK1 phosphorylation. (A) A time course of PDK1 phosphorylation (pPDK)
was performed to determine the optimal time point for maximum detection of pPDK1, which was achieved within 10 minutes of LPS/CHX treatment.
(B) Cell lysates of Tat-expressing CHME5 cells treated for 20 minutes in the presence and absence of LPS/CHX. pPDK1 data were normalized to b-actin
and the mean values are shown below the blot. Data are representative from two independent studies.
doi:10.1371/journal.pone.0021781.g005
Figure 6. Determining the effects of the screened compounds
on membrane localization of Akt. (A) Tat-expressing CHME5 cells
were treated with 20 mM of the different drugs and LPS/CHX before
having compartmental protein extraction done. Membrane fractions
were then analyzed by western blot analysis for total Akt level. PTEN
was used as an internal loading control, since it is present on the
membrane and its level does not change under different treatment
conditions (Figure 4B). (B) Human lung fibroblasts were transduced
with Adenoviral vectors containing eGFP (control) or PH-Akt-eGFP and
were treated with epithelial growth factor (EGF). Control cell picture
(control) is eGFP. EGF picture is Akt-PH-eGFP expressing cells. EGF + LA
picture is Akt-PH-eGFP expressing cells treated with Lancemaside A1.
Akt-PH-eGFP localization to the plasma membrane was determined
using a fluorescence microscope. Red scale bar indicates 20 mm
distance.
doi:10.1371/journal.pone.0021781.g006
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compounds for anti-PI3K/Akt activity. Among those screened
compounds, we identified three different compounds: Lancema-
side A1, Arctigenin and Compound K, which antagonized the
cytoprotective function of HIV-1 Tat in CHME5 cells during
LPS/CHX stress (Figure 1B).
In our extensive and detailed mechanistic analyses, we found
these three compounds to target different signals of the PI3K/Akt
pathway. First, none of these compounds influence the level of
PTEN, a negative regulator of the PI3K/Akt pathway. Second,
Arctigenin is the only compound that affects the level of PIP3 and
thus it likely targets PI3K. In fact, Arctigenin was previously
reported as Akt inhibitor with potential anti-cancer effects [33].
This confirms that our Tat-expressing CHME5 model is effective
at identifying anti-PI3K/Akt agents. Third, Akt phosphorylation
requires the membrane migration of Akt. Lancemaside A1 clearly
blocked the membrane migration of Akt as monitored by Akt-PH-
GFP localization and by western blot analysis of membrane
fractionation for Akt (Figure 6). Thus, these data directly support
the hypothesis that Lancemaside A1 inhibits the PI3K/Akt
pathway by targeting the membrane migration of Akt. Lastly,
Compound K showed relatively weak signaling responses,
compared to Lancemaside A1 and Arctigenin. However unlike
Arctigenin and Lancemaside A1, Compound K did inhibit Akt
activity, yet without reducing PI3K activity or blocking Akt
membrane migration. Thus, these data support the idea that
Compound K may directly inhibit Akt activity. More interestingly,
when we investigated the downstream effectors of Akt, Lancema-
side A1 and Arctigenin showed inhibitory effects against
phosphorylation of mTOR, GSK3b and Bad. However, Com-
pound K consistently and significantly reduced phosphorylation of
GSK3b and Bad. Possibly, Compound K may target Akt kinase
activity only for a few substrates, whereas Lancemaside A1 and
Arctigenin may universally inhibit the downstream signals of the
PI3K/Akt pathway. These mechanistic studies clearly support that
the Tat-expressing CHME5 model system was able to screen anti-
PI3K/Akt pathway molecules targeting diverse mechanistic steps
of this pathway.
Recently Lancemaside A has been reported to control blood
testosterone level in mice [34], as well as inhibiting LPS-induced
inflammation [35]. Compound K has previously been identified as
a putative anti-cancer agent [25,36]. It can regulate metabolism
via AMPK activation [37]. In addition, it has shown to regulate
p38 and Akt [38], but has also been studied for its affects as an
antidepressant [39]. Arctigenin has also been identified as an anti-
cancer agent. It has the ability to inhibit STAT3 signaling pathway
[40]. Recently, Arctigenin has been shown to inhibit IL-2 and
interferon gene expression in T cells [41]. Collectively, these data
suggest that all three compounds identified as PI3K/Akt pathways
inhibitors by our screen also have additional effects on cells.
Figure 7. Evaluating the effects of the screened compounds on phosphorylation of mTOR and pBad. (A) A time course for mTor
phosphorylation was done to optimize the assay. Maximum level of p-mTor was detected at 105 minutes after LPS/CHX treatment. (B) p-mTor level
in Tat-expressing CHME5 cell lysates from different treatment conditions were examined at 105 minutes, and levels of p-mTor were normalized to b-
actin. Averages of the data are shown below each blot. (C) Time course Bad phosphorylation was determined to optimize the assay, and maximum
level of pBad was also detected at 105 minutes after LPS/CHX treatment. (D) pBad level in Tat-expressing CHME5 cell lysates from different treatment
conditions were examined at 105 minutes, and levels of p-Bad were analyzed as described for mTor.
doi:10.1371/journal.pone.0021781.g007
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phenotype of CHME5 cells is an effective screening system for
agents targeting the PI3K/Akt pro-survival phenotype, which is
commonly observed in cancer cells and cell types infected by
several human pathogens. We have further pursued using
Compound K as an anti-cancer agent in vivo (manuscript in
preparation). We are encouraged by our results and believe
additional tests should be conducted using various cancer models
and virus-infection models in order to confirm the efficacy of the
screened compounds as anti-cancer and anti-viral agents.
Supporting Information
Data S1 Live/Dead staining of Tat-expressing CHME5
cells. Tat-expressing CHME5 cells were treated with and without
50 mg/ml LPS and 10 mg/ml cycloheximide for 24 hours in the
presence of 10 mM Lancemaside A1, Arctigenin or Compound K.
The Live/Dead assay (Invitrogen) stains dead cells with ethidium
homodimer (red) and live cells with calcein (green). Images were
captured using a fluorescent microscope. Images were manually
counted to determine the numbers of live and dead cells.
(TIF)
Data S2 Cell death for CHME5 control cells at different
concentrations of drugs. The Live/Dead assay was done, as
described in Data S1, for the three different drugs at 5, 10 and
20 mM. The percentage cell death was plotted as mean and SEM
for the three compounds.
(TIF)
Data S3 PIP3 standard curve and data. (A) Western dot
blot analysis was done to generate a standard curve using 0.5, 1, 2,
4 and 5 pmoles of PIP3. Data were plotted to find the slope and y-
intercept. (B) One representative data set is shown for lysates of
Tat-expressing CHME5 cells treated under conditions. LPS/CHX
treatment was 50 mg/ml LPS and 10 mg/ml cycloheximide.
Lancemaside A1 (LA), Arctigenin (AR), Compound K (CK) and
Wortmannin (WM).
(TIF)
Table S1 Western blots were analyzed. Data was normal-
ized to either total proteins (Akt and GSK-3b)o rb-actin (p-mTor,
pBad, p-PDK1 and PTEN). Data of means and standard
deviations from the western blot analysis are shown. Control
lanes were set to 1.00. LPS is the positive control. Changes in
intensities are shown for the different drug treatment groups.
(TIF)
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